These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37788106)

  • 1. Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma.
    Sada I; Harada Y; Hiyama T; Mizukami M; Kan T; Kawai M; Kiuchi Y
    Melanoma Res; 2023 Dec; 33(6):539-546. PubMed ID: 37788106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
    Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
    Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
    Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
    J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Incidence of Incident Noninfectious Uveitis in Patients Treated With BRAF Inhibitors: A Nationwide Clinical Cohort Study.
    Jung H; Kim S; Lee CS; Byeon SH; Kim SS; Lee SW; Kim YJ
    Am J Ophthalmol; 2024 Nov; 267():142-152. PubMed ID: 38977151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vogt-Koyanagi-Harada disease-like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA-DRB1*04.
    Amagai R; Fujimura T; Yamazaki E; Takahashi M; Tamabuchi E; Kambayashi Y; Hashimoto A; Hashimoto K; Asano Y
    J Dermatol; 2024 Jun; 51(6):854-857. PubMed ID: 38111371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of melanoma complicated with uveitis induced by two types of BRAF/MEK inhibitors and nivolumab treatment.
    Obaru C; Kimura T; Yamamura M; Kuriyama H; Kashiwada-Nakamura K; Mizuhashi S; Matsumura T; Watanabe T; Inoue T; Fukushima S
    J Dermatol; 2024 Apr; 51(4):e115-e117. PubMed ID: 37927219
    [No Abstract]   [Full Text] [Related]  

  • 7. [Induction of Uveitis by Immune-Oncologic Therapies, Namely Checkpoint Inhibitors].
    Garweg JG
    Klin Monbl Augenheilkd; 2022 Apr; 239(4):575-581. PubMed ID: 35472809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.
    Awada G; Schwarze JK; Tijtgat J; Fasolino G; Kruse V; Neyns B
    Melanoma Res; 2022 Jun; 32(3):183-191. PubMed ID: 35377866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
    Arangalage D; Degrauwe N; Michielin O; Monney P; Özdemir BC
    Cancer Treat Rev; 2021 Nov; 100():102282. PubMed ID: 34438238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases.
    Fujisawa Y; Ito T; Kato H; Irie H; Kaji T; Maekawa T; Asai J; Yamamoto Y; Fujimura T; Nakai Y; Yasuda M; Matsuyama K; Muto I; Matsushita S; Uchi H; Nakamura Y; Uehara J; Yoshino K
    Eur J Cancer; 2021 Mar; 145():210-220. PubMed ID: 33503528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
    Samlowski W; Adajar C
    BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
    Trojaniello C; Vitale MG; Ascierto PA
    Curr Opin Oncol; 2021 Mar; 33(2):133-138. PubMed ID: 33399314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ocular side effects of modern oncological therapy : Immunological checkpoint and MEK/BRAF signal transduction inhibitors].
    Thurau S; Wildner G; Gamulescu MA
    Ophthalmologie; 2023 May; 120(5):559-573. PubMed ID: 37160621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
    Madoe A; Schauwvlieghe PP; Jacob J
    Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
    Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G
    Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience.
    Comito F; Aprile M; Pagani R; Siepe G; Sperandi F; Gruppioni E; Altimari A; De Biase D; Melotti B
    Melanoma Res; 2022 Dec; 32(6):477-484. PubMed ID: 36039514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
    Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
    Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment.
    Braun D; Getahun D; Chiu VY; Coleman AL; Holland GN; Yu F; Gordon LK; Sun MM
    Am J Ophthalmol; 2021 Apr; 224():282-291. PubMed ID: 33359682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
    Choe CH; McArthur GA; Caro I; Kempen JH; Amaravadi RK
    Am J Ophthalmol; 2014 Oct; 158(4):831-837.e2. PubMed ID: 25036880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.